Past Papers · SAQ

Antibacterials — Piperacillin-Tazobactam vs Ciprofloxacin

Current · V5 (2025) → O2.i Historical · V4 (2023) → T2.i 1 exam appearance

2019B Q20

Exam question

Compare the pharmacology of piperacillin-tazobactam and ciprofloxacin.

CICMWrecks answer

Master answer

Canonical sourceCanonical Pharmacopeia comparison
Open in Pharmacopeia
Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field PIPERACILLIN -TAZOBACTAM
Anti-infectives · Anti-infectives
CIPROFLOXACIN
Anti-infectives · Anti-infectives · Level 3
Mechanism of action

β lactam antibiotic
Binds to penicillin binding protein (transpeptidase) and
prevents crosslinking of bacterial peptidoglycan
impairs cell wall synthesis

Bacteriocidal antimicrobials that block DNA replication by blocking tropoisomerase enzymes, which are essential for the supercoiling, replication and separation of circular bacterial DNA

Absorption

Poorly absorbed orally
Peak plasma concentrations occur immediately after the completion of intravenous infusion. Following several doses of piperacillin-tazobactam infusions every 6 hours, peak concentrations were similar to those that were measured after the initial dose.

Good oral absorption (80%)

Undergoes first pass

Coadministration of calcium or magnesium reduces absorption

Distribution

Widely distributed in body tissues and fluids.

Meningeal distribution of piperacillin-tazobactam increases with inflammation, but is otherwise low

High CSF and tissue penetration

Protein binding

30% PB

30% PB

Volume of distribution

Vd <1L/kg

Vd 2-3L/kg

Metabolism

Piperacillin is not metabolized in man.

Tazobactam is mainly metabolized to M1, an inactive metabolite.

Little hepatic metabolism

Excretion

Renal: 80% unchanged + metabolite

Active tubular secretion

Half-life

Half-life of Piperacillin-tazobactam: 0.7 to 1.2 hours

T1/2= 3 hours (renal dose adjustment required)

Adverse Effects Toxicity

1. Hypokalaemia (lower sodium concentration so hypernatraemia less likely)
2. Piptaz + vancomycin associated with increased AKI
3. LFT derangement
Neutropenia

1. CNS Toxicity- GABA antagonists and may precipitate seizures in epileptic patients, particularly in presence of NSAIDs
2. Tendonitis and tendon rupture
3. QT prolongation- Low risk of Torsade’s in absence of other predisposing factors
4. Hemolysis in G6PD
5. Photosensitivity
6. Arthralgias and cartilage toxicity (generally avoided in children)
7. Dysglycaemia (hyper and hypoglycaemia)

Antimicrobial Spectrum

Pseudomonas
Beta-lactamase producing bacteria
Gram negatives
Anaerobes

Broad spectrum
Active against both gram positive and gram negative bacteria

particularly effective against
GNB (E.Coli, H.influenza, Klebsiella, Legionella, Moraxella, Proteus, and Pseudomonas)
Less effective against Gram-positive bacteria (such as MSSA, Strep pneumoniae, and Enterococcus faecalis) than newer fluoroquinolones

Class Group

ANTIBIOTIC:
PENICILLIN

ANTIBIOTIC:
QUINOLONE

Indications Uses

used to treat a variety of infections, including those caused by aerobic and facultative gram-positive and gram-negative bacteria, in addition to gram-positive and gram-negative anaerobes.
E.g: cellulitis, diabetic foot infections, appendicitis, and postpartum endometritis infections.

—
Introduction

Antipseudomonal penicillin

Quinolone

Legacy Cicm Level

Level 1

Level 3

Presentation —

PO and IV, topical eye drops and ointment

Resistance Mechanism

Certain gram-negative bacilli infections with beta-lactamase producing organisms cannot be treated with piperacillin-tazobactam, due to a gene mutation conferring antibiotic resistance

Alteration in target enzyme – changes to the DNA binding surface of DNA supergyrase infers resistance
Alteration in drug entry – altered expression of outer membrane porin proteins that form channels for passive diffusion of ciprofloxacin
Increase in efflux of drug – expression of nonspecific energy dependent efflux pumps which remove drug

Special Points

Removed by haemodialysis

—

Past papers

Exam appearances

1 appearance
Exam Exact exam wording Candidate success
2019B Q20 Compare the pharmacology of piperacillin-tazobactam and ciprofloxacin. 58%